Scynexis Inc is a biotechnology company focused on developing innovative therapies to combat serious infections, particularly those caused by resistant pathogens. The company specializes in researching and advancing novel antifungal treatments aimed at addressing unmet medical needs in infectious diseases. By leveraging its proprietary drug development platform, Scynexis seeks to create transformative solutions that enhance patient outcomes and improve the management of challenging infections in both hospital and outpatient settings. Through its commitment to scientific excellence and rigorous clinical testing, Scynexis strives to make a meaningful impact on public health by providing effective alternatives for patients facing difficult-to-treat infections. Read More
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Let's delve into the US markets on Friday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
WHY: NEW YORK, NY - (NewMediaWire) - January 8, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of SCYNEXIS, Inc. (NASDAQ: SCYX) between March 31, 2023 and September 22, 2023, both dates inclusive (the “Class Period”), of the important January 8, 2024 lead plaintiff deadline.
NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) (NASDAQ: SCYX) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired SCYNEXIS securities between March 31, 2023 and September 22, 2023, both dates inclusive (the “Class Period”). Investors have until January 8, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
If you suffered losses exceeding $25,000 investing in Scynexis securities between March 31, 2023 and September 22, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/SCYX.
